Thrombolytic therapy in acute myocardial infarction  by Kennedy, J.Ward
Thrombolytic Therapy in
Acute Myocardial Infarction
J. Ward Kennedy, MD, MACC
Seattle, Washington
The following review summarizes one of the early random-
ized controlled trials of the use of thrombolytic therapy for
acute myocardial infarction. The results of this and other
smaller trials carried out in the early 1980s redirected the
therapy of acute myocardial infarction from a strategy of
reducing myocardial work and arrhythmia suppression to
one of early reperfusion of the infarcting myocardium. The
reduction in morbidity and mortality that have resulted
from this shift in management can be compared in impor-
tance to the introduction and development of coronary
artery bypass surgery and coronary artery angioplasty.
Early Thrombolysis in
Acute Myocardial Infarction:
Limitation of Infarct
Size and Improved Survival
by M. L. Simoons, P. W. Serruys, M. van den Brand,
J. Res, F. W. Verheugt, X. H. Krauss, W. J. Remme,
F. Bar, C. de Zwaan, A. van der Laarse, Vermeer, and
Lubsen (1)
ABSTRACT
The effect of thrombolysis in acute myocardial infarction on
infarct size, left ventricular function, clinical course and patient
survival was studied in a randomized trial comparing throm-
bolysis (269 patients) with conventional treatment (264 control
patients). All 533 patients were admitted to the coronary care
unit within 4 hours after the onset of symptoms related to the
infarction. Baseline characteristics were similar in both groups.
Informed consent was requested only of patients allocated to
thrombolysis; no angiography was performed in 35. The infarct-
related artery was patent in 65 patients and occluded in 169.
Recanalization was achieved in 133 patients. The median time
to angiographic documentation of vessel patency was 200
minutes after the onset of symptoms.
The clinical course in the coronary care unit was more
favorable after thrombolysis. Infarct size, estimated from myo-
cardial enzyme release, was 30% lower after thrombolysis. In
patients admitted within 1 hour after the onset of symptoms the
reduction of infarct size was 51%, in those admitted between 1
and 2 hours it was 31% and in those admitted later than 2
hours it was 13%. Left ventricular function measured by
radionuclide angiography before hospital discharge was better
after thrombolysis (ejection fraction 48 6 15%) than in control
patients (44 6 15%). Similar improvement was observed in
patients with a first infarct only (thrombolysis 50 6 14%,
control subjects 46 6 15%), in patients with anterior infarction
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INTRODUCTION
In this edition of the Journal, we release the seventh in a series
of reviews of influential articles that have been previously
published in ACC journals, including the American Journal of
Cardiology (from 1958 to 1982) and JACC (from 1983 to the
present). The publication of these articles is only one aspect of the
ACC’s 50th anniversary commemoration, which highlights 50
years of leadership in cardiovascular care and education. The
articles are intended to encourage reflection on the remarkable
progress made in cardiovascular medicine over time, as well as to
acknowledge the amazing prescience of some early investigators in
anticipating and, in many cases, later guiding developments in
their field.
The working group responsible for selecting these articles and
asking reviewers to write editorials solicited suggestions from
the ACC’s clinical committees and individual members.
The group achieved consensus fairly easily, including whom the
group should ask to prepare the accompanying editorials. We
initially drew up a list of 14 general areas to cover in this series,
but later found that there are several major areas of modern
cardiology, prominently molecular cardiology, in which the truly
landmark articles have, alas, not yet been published in JACC.
Therefore, the working group decided not to categorize by subject,
but instead, to concentrate on the most important articles.
The working group, a task force of the Subcommittee for the
Commemoration of the ACC 50th Anniversary, owes a great
deal to Ms. May A. Roustom and the efficient and tireless staff
at Heart House for facilitating this project. We also wish to
thank all who suggested articles and, most important, the
authors who prepared reviews for their willingness to contribute
their time and wisdom.
Influential Articles in JACC Working Group
Sharon A. Hunt, M.D., F.A.C.C.
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(thrombolysis 44 6 16%, control subjects 35 6 14%) and in
those with inferior infarction (thrombolysis 52 6 12%, control
subjects 49 6 12%). Similar results were obtained by contrast
angiography.
Mortality was lower after thrombolysis. After 28 days 16
patients allocated to thrombolysis and 31 control patients had
died. One year survival rates were 91 and 84%, respectively.
On the other hand, nonfatal reinfarction occurred more fre-
quently after thrombolysis (36 patients) than in control subjects
(16 patients). Early thrombolysis by intracoronary streptokinase
leads to a smaller infarct size estimated by enzyme release,
preserves left ventricular function at the second week and leads
to improved 1 year survival.
Originally published in the Journal of the American College of Cardiology,
April 1986.
Review
Historical Background. Before 1980, the management of
patients with acute myocardial infarction (AMI) was cen-
tered around pharmacologic therapy directed toward man-
aging arrhythmias and attempting to limit the size of the
evolving infarct. Although these efforts were partially effec-
tive, the morbidity and mortality from AMI remained high.
In the mid 1970s, a group of cardiologists and cardiac
surgeons in private practice in Spokane, Washington, began
a program of urgent coronary angiography on patients
presenting to the emergency department with evolving
myocardial infarctions to select those who might benefit
from emergency coronary bypass surgery. From this expe-
rience, later reported by DeWood et al. (2), they demon-
strated that emergency angiography could be performed
safely in this group of patients. They also observed that in
most patients presenting with ST elevation on the electro-
cardiogram, immediate coronary angiography identified a
thrombotic occlusion of the infarct-related artery. Although
urgent bypass surgery never became widely accepted as a
primary therapy for AMI, these observations provided
critical background information for the later development of
both thrombolytic therapy and primary angioplasty for the
management of AMI.
In 1979, two European investigators reported new ap-
proaches to the management of coronary artery disease in
U.S. publications. Rentrop et al. reported the successful use
of intracoronary streptokinase (ICSK) for reperfusion of
patients with AMI, and Gruentzig et al. described the
development of percutaneous transluminal coronary angio-
plasty (3,4). Although angioplasty, early in its development,
was not yet suitable for use in the setting of acute infarction,
ICSK therapy could be performed in any catheterization
laboratory without special equipment or training. For this
reason, ICSK therapy was rapidly introduced into clinical
practice by cardiologists in Europe and North America;
academic medical centers in Detroit, Salt Lake City, Seattle,
Auckland, New Zealand, and Simoons’s group in the
Netherlands initiated randomized controlled trials of this
new therapy.
The working group on thrombolytic therapy in AMI of
the Netherlands Interuniversity Cardiology Institute began
their randomized controlled trial in May 1981, and their
early results were published in April 1986 (1). These
investigators randomized 533 patients to either ICSK or
conventional management in a coronary care unit. The
initial protocol required patients in whom an occluded
infarct-related artery was identified and who were in the
active treatment arm to undergo coronary angiography
followed by ICSK. Later in the trial, patients allocated to
thrombolytic therapy received an initial intravenous dose of
500 mg of streptokinase before cardiac catheterization to
reduce the time from diagnosis to initiating thrombolytic
therapy. In addition, when angioplasty became available, 35
patients who had an unsatisfactory result from ICSK un-
derwent immediate angioplasty of the infarct-related lesion.
Thus, the Netherlands investigators tested a strategy of early
reperfusion therapy for AMI that utilized a combination of
immediate coronary angiography followed by ICSK, intra-
venous streptokinase followed by coronary angiography and
ICSK and, later in the trial, angioplasty when thrombolytic
therapy failed. By changing the treatment protocol as new
methods became available, these investigators attempted to
achieve coronary artery reperfusion as early and as com-
pletely as possible with the drugs and techniques available to
them at that time.
Early results of thrombolytic therapy. In the Netherlands
trial, the cumulative distribution of infarct size as estimated
by serial enzyme measurements averaged 30% smaller in the
treatment patients as compared with the control subjects
(p 5 0.0001). The left ventricular ejection fraction (EF) was
measured by radionuclide angiography 10 to 20 days after
infarction and was 4% higher in the lytic patients as
compared with the control subjects (p 5 0.05). At 28 days
of mean follow-up, total mortality rate was reduced by 50%
in the treatment patients as compared with the control
subjects (5.9% vs. 11.7%). At the time of intermediate
follow-up, which varied from 1 to 48 months, there con-
tinued to be a 45% reduction in mortality in the treatment
group as compared with the control subjects. There were 35
patients who were allocated to thrombolytic therapy who
did not undergo angiography or receive streptokinase. As
required by the Zellen technique of randomization used in
this trial, these patients were included in the data analysis as
being in the treatment group. In this group, there was a high
early mortality of 14.3%. In comparison, patients who had
an open vessel at the time of initial diagnostic angiography
or after successful reperfusion with ICSK had a remarkably
low mortality of 4.5%. Among the 36 patients who failed to
reperfuse with ICSK, nine (25%) died. These results dem-
onstrated the profound beneficial effect of early coronary
artery reperfusion on mortality in patients with AMI. These
results also confirmed those of the smaller 250-patient
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Western Washington Randomized Trial of Intracoronary
Streptokinase in Acute Myocardial Infarction, which re-
ported similar reductions in mortality (3.7% vs. 11.2%, p 5
0.02) with ICSK, and identified the importance of complete
reperfusion for the long-term outcome of patients treated
with thrombolytic therapy (5,6).
Long-term follow-up of thrombolytic trials. Long-term
follow-up has been published from the Netherlands trial,
the combined results of three Western Washington trials
and the two early megatrials of intravenous streptokinase
therapy ISIS-2 and GISSI-1 (7–10). The Netherlands
investigators were the first to publish their long-term
follow-up. They reported a sustained benefit of thrombo-
lytic therapy over three to seven years. The survival curve for
the treatment and control patients is shown in Figure 1.
After three years, the mean survival of the lytic patients was
87% versus 79% for the control subjects, and the five-year
survival had a similar benefit in favor of thrombolytic
therapy (81% vs. 71%). The overall reduction in five-year
mortality for the treatment patients was 39% compared with
the control subjects. The shape of the survival curve dem-
onstrates that the benefits of thrombolytic therapy occur
during the first few months after AMI, and after that period
of time the survival of the two groups is similar. Both the
ISIS-2 and GISSI-1 trials demonstrated the same pattern of
survival over 10 years of follow-up (9,10).
Follow-up angiographic findings predict long-term out-
come. During the first three years of follow-up in the
Netherlands trial, reinfarction was more common in the
lytic patients than in the control subjects. This occurred
most often in those with initial inferior infarctions. There
were 422 patients with a follow-up angiogram between 10
and 40 days after admission into the trial in whom an
angiographic ejection fraction could be determined. Among
these patients, the five-year survival for those with an EF
.40% was similar in the treatment and control patients,
being 83% and 86%, respectively. For those with an EF of
,40%, the lytic patients had improved long-term survival
(65% vs. 57%). The severity of the residual stenosis in the
infarct-related coronary artery on follow-up angiography
was also an important predictor of long-term outcome. In
patients with a residual stenosis ,90%, the five-year survival
was 94% for treatment patients and 80% for control pa-
tients. For those with a residual stenosis .90%, lytic therapy
did not improve five-year survival, which was 78% in both
groups. Thus, in patients in this trial who survived to have
a follow-up angiogram, those with good residual left ven-
tricular function had excellent long-term survival regardless
of whether or not they had received thrombolytic therapy.
When thrombolytic therapy was unsuccessful or when a
high grade stenosis persisted after lytic therapy, the outcome
was less favorable. As has been apparent for several years,
left ventricular ejection fraction is an important predictor of
long-term outcome after myocardial infarction (MI) inde-
pendent of the form of therapy provided to the patient. This
trial helped establish this fact and the additional importance
of the severity of the residual stenosis in the infarct-related
vessel after therapy for patients’ long-term survival.
CONCLUSIONS
Early reperfusion of the infarct-related coronary artery is the
cornerstone of the current management of AMI. The
Netherlands trial provided one of the important steps in the
development of this therapy. Although it is traditional for
clinical trials to maintain a rigid protocol for the duration of
the study, the Netherlands investigators chose to change
their strategy of reperfusion as new forms of therapy became
available. Because these researchers adopted an unorthodox
approach to clinical investigation, the results of this study
contributed to the rapid evolution of reperfusion therapy.
The best way to accomplish reperfusion in patients with
evolving MI continues to be debated, although there is
strong agreement that very early reperfusion must be ac-
complished to preserve myocardium. In addition, normal or
nearly normal flow (Thrombolysis in Myocardial Infarction
grade 3) must be established in the infarct-related vessel to
provide optimal reduction in morbidity and mortality
(11,12). The early and long-term results of primary PTCA
have been demonstrated to be excellent when carried out in
an experienced laboratory by expert interventionists (13).
Intravenous thrombolytic therapy, when applied in the first
1 to 2 h after the onset of AMI, also yields good results, but
despite the development of many new thrombolytic agents,
there remains a relatively high incidence of intracranial
hemorrhage. It now appears that a combination of platelet
glycoprotein IIb/IIIa inhibitors and a lower dose of throm-
bolytic agents may be superior to any of the pharmacologic
revascularization strategies currently in use (14). There is
now at least a reasonable hope that in the near future
Figure 1. Survival analysis of all 533 patients allocated to intra-
coronary streptokinase or conventional therapy (control). Numbers
denote patients at risk at the various intervals after treatment with
streptokinase (top) or conventional therapy (below). Follow-up
data were complete at three years. From Simoons et al. (7).
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pharmacologic therapy that is the equal of primary angio-
plasty will be available in every community hospital in the
U.S. If this occurs, we can anticipate a further important
reduction in the morbidity and mortality that result from
MI.
Reprint requests and correspondence: Dr. Kennedy, Cardiology
IIIC, 1660 South Columbian Way, Box 358280-IIIC, Seattle,
Washington 98108-1597.
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